Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Phase 2 trial of docetaxel and gefitinib in the first-line treatment of patients with advanced nonsmall-cell lung cancer (NSCLC) who are 70 years of age or older.

Cancer - 1 May 2008

Simon George R, Extermann Martine, Chiappori Alberto, Williams Charles C, Begum Mubeena, Kapoor Rachna, Haura Eric B, Ismail-Khan Roohi, Schell Michael J, Antonia Scott J, Bepler Gerold

Abstract excerpt

BACKGROUND: This is a phase 2 study of chemotherapy-naive patients, 70 years of age or older, with nonsmall-cell lung cancer (NSCLC) who were treated with docetaxel and gefitinib. The primary endpoint was response rate (RR). Secondary endpoints were overall survival (OS) and progression-free survival (PFS). METHODS: Eligible patients were treated with docetaxel 75 mg/m(2) every 3 weeks and gefitinib 250 mg...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Activities of Daily Living
Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Non-Small-Cell Lung

Share to Comorbidity

Share to Docetaxel

Share to Gefitinib

Share to Quinazolines

Share to Taxoids

Source

Identifiers

PMID: 18300255
DOI: 10.1002/cncr.23360

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 8 closest

Phase 2 trial of docetaxel and gefitinib in the first-line treatment of patients with advanced nonsmall-cell lung cancer (NSCLC) who are 70 years of age or older.PMID 18300255Read ↗

First-line gefitinib in patients aged 75 or older with advanced non-small cell lung cancer harboring epidermal growth factor receptor mutations: NEJ 003 study.Semantic proximity Read ↗

Phase III randomized, placebo-controlled trial of docetaxel with or without gefitinib in recurrent or metastatic head and neck cancer: an eastern cooperative oncology group trial.Semantic proximity Read ↗

Randomized phase III trial of erlotinib versus docetaxel as second- or third-line therapy in patients with advanced non-small-cell lung cancer: Docetaxel and Erlotinib Lung Cancer Trial (DELTA).Semantic proximity Read ↗

A randomized phase II study of docetaxel or pemetrexed with or without the continuation of gefitinib after disease progression in elderly patients with non-small cell lung cancer harboring EGFR mutations (JMTO LC12-01).Semantic proximity Read ↗

Association between age at diagnosis and the presence of EGFR mutations in female patients with resected non-small cell lung cancer.Semantic proximity Read ↗

The qualification of docetaxel or erlotinib for second-line therapy should be based on clinical and molecular predictive factors.Semantic proximity Read ↗

Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial.Semantic proximity Read ↗

Prognostic factors in non-small cell lung cancer patients who are recommended to receive single-agent chemotherapy (docetaxel or pemetrexed) as a second- or third-line chemotherapy: in the era of oncogenic drivers and molecular-targeted agents.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.